Comparison of efficacy and safety between standard-dose and modified-dose FOLFIRINOX as a first-line treatment of pancreatic cancer

doi:10.4251/wjgo.v10.i11.421

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 11

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6923)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-4) series.

Item

Count

PDF

464

WORD

260

HTML

3886

Figures (1-2)

161

Tables (1-4)

161

Sum=4932

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

942

Download

1049

Sum=1991

Nov 15, 2018 (publication date) through Apr 23, 2024

Times Cited of This Article

Times Cited (26)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Oncol. Nov 15, 2018; 10(11): 421-430
Published online Nov 15, 2018. doi: 10.4251/wjgo.v10.i11.421

Table 1 Pretreatment characteristics

	sFOLFIRINOX	mFOLFIRINOX	P value
	(n = 88)	(n = 42)	P value
Sex, n (%)			0.004¹
Male	61 (69.3)	18 (42.9)
Female	27 (30.7)	24 (57.1)
Age, yr			0.018¹
Median (range)	57 (31-79)	63.5 (41-77)	0.018¹
ECOG-PS, n (%)			0.426
0	68 (77.3)	35 (83.3)
1	20 (22.7)	7 (16.7)
Laboratory test results, median (range)
Absolute neutrophil count, /μL	4200 (1610-11170)	4525 (2080-18930)	0.317
Hemoglobin, g/dL	12.3 (7.1-17.1)	12.1 (8.5-14.9)	0.36
Platelet count, × 10³/μL	218 (76-439)	245 (107-764)	0.247
Total bilirubin, mg/dL	0.7 (0.2-4.8)	0.5 (0.2-2.7)	0.144
Albumin, g/dL	3.9 (2.8-5.0)	3.9 (2.4-4.8)	0.797
Creatinine, mg/dL	0.67 (0.37-1.02)	0.70 (0.37-1.04)	0.516
Level of CA 19-9
U/mL, median (range)	172.2 (0.6-20000.0)	455.5 (0.7-20000.0)	0.709
Normal, n (%)	17 (19.3)	11 (21.5)	0.274
Elevated, < 59 × ULN, n (%)	53 (60.2)	19 (45.2)
Elevated, ≥ 59 × ULN, n (%)	18 (20.5)	12 (28.6)
Biliary drainage, n (%)			0.435
Presence	29 (33.0)	11 (26.2)	0.435
Tumor location in pancreas, n (%)			0.657
Head	40 (45.5)	16 (38.1)
Body and tail	44 (50.0)	23 (54.8)
Recurrent	4 (4.5)	3 (7.1)
Tumor size, cm			0.313
Median (range)	3.6 (1.3-7.7)	4.0 (1.3-8.0)	0.313
Disease extent, n (%)			0.243
Borderline resectable	17 (19.3)	6 (14.3)
Locally advanced	26 (29.5)	8 (19.0)
Metastatic	45 (51.1)	28 (66.7)
Stage, n (%)			0.248
II	24 (27.3)	8 (19.0)
III	19 (21.6)	6 (14.3)
IV	45 (51.1)	28 (66.7)
Prior treatment, n (%)
Naïve	75 (85.2)	33 (85.7)	0.941
Curative resection	4 (4.5)	4 (9.5)	0.272
CCRT	9 (10.2)	4 (9.5)	1.000

¹Values indicate statistical significance. mFOLFIRINOX: Modified FOLFIRINOX; sFOLFIRINOX: Standard FOLFIRINOX; ECOG-PS: Eastern Cooperative Oncology Group performance status; ULN: Upper limit of normal range; CA: Carbohydrate antigen; CCRT: Concurrent chemoradiotherapy.

Table 2 Treatment characteristics

	sFOLFIRINOX	mFOLFIRINOX	P value
	(n = 88)	(n = 42)	P value
Number of cycles administered, median (range)	9.5 (4-24)	12 (4-32)	0.421
Treatment duration, d, median (range)	126 (42-322)	154 (42-434)	0.595
RDI to sFOLFIRINOX, %, median (range)
Oxaliplatin	85.3 (56.3-100)	75.0 (51.1-75.0)	< 0.001¹
Irinotecan	85.0 (56.3-100)	75.0 (51.1-75.0)	< 0.001¹
5-FU (bolus)	92.1 (21.4-100)	75.0 (51.1-75.0)	< 0.001¹
5-FU (infusion)	94.1 (56.3-100)	75.0 (51.1-75.0)	< 0.001¹
Patients with ≥ 1 dose reduction, n (%)	62 (70.5)	16 (38.1)	< 0.001¹
Cause of dose reduction (> 5%), n (%)
Neutropenia	53 (60.2)	9 (21.4)	< 0.001¹
Febrile neutropenia	10 (11.4)	4 (9.5)	1.000
Patients with ≥ 1 dose delay, n (%)	55 (62.5)	22 (52.4)	0.272
Cause of dose delay (> 5%), n (%)
Neutropenia	16 (18.2)	5 (11.9)	0.363
Febrile neutropenia	16 (18.2)	5 (11.9)	0.363
Fatigue	7 (8.0)	8 (19.0)	0.081
No. of G-CSF administered, median (range)	3.5 (0-24)	2 (0-12)	0.043¹
Patients received G-CSF, n (%)	72 (81.8)	27 (64.3)	0.028¹

¹Values indicate statistical significance. mFOLFIRINOX: Modified FOLFIRINOX; sFOLFIRINOX: Standard FOLFIRINOX; RDI: Relative dose intensity; 5-FU: 5-Fluorouracil; G-CSF: Granulocyte colony-stimulating factor.

Table 3 Response evaluation n (%)

	sFOLFIRINOX	mFOLFIRINOX	P value
	(n = 88)	(n = 42)	P value
CR	1 (1.1)	1 (2.4)
PR	34 (38.6)	14 (33.3)
SD	36 (40.9)	20 (47.6)
PD	17 (19.3)	7 (16.7)
Objective response^a	35 (39.8)	15 (35.7)	0.656
Disease control^b	71 (80.7)	35 (83.3)	0.716

^aObjective response includes CR and PR;

^bDisease control includes CR, PR, and SD. mFOLFIRINOX: Modified FOLFIRINOX; sFOLFIRINOX: Standard FOLFIRINOX; CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease.

Table 4 Adverse events (≥ Grade 3) n (%)

Event	sFOLFIRINOX	mFOLFIRINOX	P value
Event	(n = 88)	(n = 42)	P value
Hematologic
Neutropenia	73 (83.0)	28 (66.7)	0.044¹
Febrile neutropenia	24 (27.3)	9 (21.4)	0.474
Anemia	19 (21.6)	11 (26.2)	0.561
Thrombocytopenia	8 (9.1)	2 (4.8)	0.499
Non-hematologic
Fatigue	33 (37.5)	14 (33.3)	0.644
Anorexia	43 (48.9)	12 (28.6)	0.029¹
Nausea/Vomiting	53 (60.2)	19 (45.2)	0.108
Diarrhea	12 (13.6)	0 (0.0)	0.009¹
Peripheral sensory neuropathy	12 (13.6)	2 (4.8)	0.224
Sepsis	5 (5.7)	0 (0.0)	0.174
Lung infection	3 (3.4)	4 (9.5)	0.212
Biliary tract infection	6 (6.8)	0 (0.0)	0.176

¹Values indicate statistical significance. mFOLFIRINOX: Modified FOLFIRINOX; sFOLFIRINOX: Standard FOLFIRINOX.

Citation: Kang H, Jo JH, Lee HS, Chung MJ, Bang S, Park SW, Song SY, Park JY. Comparison of efficacy and safety between standard-dose and modified-dose FOLFIRINOX as a first-line treatment of pancreatic cancer. World J Gastrointest Oncol 2018; 10(11): 421-430
URL: https://www.wjgnet.com/1948-5204/full/v10/i11/421.htm
DOI: https://dx.doi.org/10.4251/wjgo.v10.i11.421